FT836 CAR T-cell Therapy
Phase I Study of FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma
Arms / Cohorts
Experimental:Dose Level 1: FT836 CAR T Cells
Not yet accepting
Experimental:Dose Level 0: FT836 CAR T Cells
Not yet accepting
Experimental:Dose Level 2: FT836 CAR T Cells
Not yet accepting
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.